The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
10.1016/S1875-5364(18)30122-5
- Author:
Yu ZHOU
1
;
Han-Bo CAO
2
;
Wen-Jun LI
2
;
Li ZHAO
3
Author Information
1. Center For Drug Evaluation, China Food and Drug Administration, Beijing 100022, China.
2. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China.
3. State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China. Electronic address: zhaoli@cpu.edu.cn.
- Publication Type:Journal Article
- Keywords:
CXCL12/CXCR4;
Plerixafor;
Targeted therapy;
Tumor
- MeSH:
Animals;
Antineoplastic Agents;
chemical synthesis;
chemistry;
pharmacology;
Biological Products;
chemistry;
pharmacology;
Chemokine CXCL12;
genetics;
metabolism;
Humans;
Molecular Targeted Therapy;
Neoplasms;
drug therapy;
genetics;
metabolism;
Receptors, CXCR4;
antagonists & inhibitors;
genetics;
metabolism
- From:
Chinese Journal of Natural Medicines (English Ed.)
2018;16(11):801-810
- CountryChina
- Language:English
-
Abstract:
Chemokine 12 (CXCL12), also known as stromal cell derived factor-1 (SDF-1) and a member of the CXC chemokine subfamily, is ubiquitously expressed in many tissues and cell types. It interacts specifically with the ligand for the transmembrane G protein-coupled receptors CXCR4 and CXCR7. The CXCL12/CXCR4 axis takes part in a series of physiological, biochemical, and pathological process, such as inflammation and leukocyte trafficking, cancer-induced bone pain, and postsurgical pain, and also is a key factor in the cross-talking between tumor cells and their microenvironment. Aberrant overexpression of CXCR4 is critical for tumor survival, proliferation, angiogenesis, homing and metastasis. In this review, we summarized the role of CXCL12/CXCR4 in cancer, CXCR4 inhibitors under clinical study, and natural product CXCR4 antagonists. In conclusion, the CXCL12/CXCR4 signaling is important for tumor development and targeting the pathway might represent an effective approach to developing novel therapy in cancer treatment.
